Деякі пероральні лікарські препарати, що використовуються для лікування нетримання сечі у дітей*
Medication | Some Adverse Effects |
|---|---|
Voiding dysfunction in daytime incontinence (bladder overactivity) | |
Oxybutynin | Confusion, dizziness, increased temperature, flushing, constipation, dry mouth |
Tolterodine | Constipation, flushing, dry mouth |
Solifenacin | Constipation, dry mouth, gastrointestinal effects, blurred vision |
Darifenacin | Constipation, dry mouth, gastrointestinal effects, blurred vision |
Mirabegron | Headache, gastrointestinal effects, nasopharyngitis, hypertension |
Enuresis | |
Desmopressin (DDAVP, arginine vasopressin) | Intranasal DDAVP is not recommended because of the risk of dilutional hyponatremia. |
Imipramine | Possible nervousness, personality change, disordered sleep, cardiac arrhythmias† Should be used only for therapy-resistant cases given risk–benefit profile Rarely, death‡ |
* These medications are mostly used as second-line therapy. Treatment of the underlying disorder and behavioral therapy should be used first. | |
† ECG should be done to identify prolongation of the QT interval and/or the corrected QT (QTc) interval, which contraindicate use of imipramine. | |
‡ Sudden death of unclear etiology has been reported. This medication is now rarely used. | |